Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical company developing prescription cannabinoid medicines - Says application has been made to the Financial Conduct Authority and the London Stock Exchange Group PLC for the redenominated ordinary shares resulting from the capital reorganisation to be admitted to the Official List. This follows the approval of a capital reorganisation by shareholders in September 2023. Oxford Cannabinoid expects around 960.4 million shares will be admitted to trading and dealings will commence on the London Stock Exchange February 16.

Current stock price: 0.48 pence

12-month change: down 41%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.